Literature DB >> 26310180

Demarcation of secondary hyperalgesia zones: Punctate stimulation pressure matters.

Thomas K Ringsted1, Casper Enghuus2, Morten A Petersen3, Mads U Werner2.   

Abstract

BACKGROUND: Secondary hyperalgesia is increased sensitivity in normal tissue near an injury, and it is a measure of central sensitization reflecting injury-related effects on the CNS. Secondary hyperalgesia areas (SHAs), usually assessed by polyamide monofilaments, are important outcomes in studies of analgesic drug effects in humans. However, since the methods applied in demarcating the secondary hyperalgesia zone seem inconsistent across studies, we examined the effect of a standardized approach upon the measurement of SHA following a first degree burn injury (BI). NEW
METHOD: The study was a two-observer, test-retest study with the two sessions separated by 6wk. An observer-blinded design adjusted to examine day-to-day and observer-to-observer variability in SHA was used. In 23 healthy volunteers (12 females/11 males) a BI was induced by a contact thermode (47.0°C, 420s, 2.5×5.0cm(2)). The SHA, demarcated by polyamide monofilaments (bending force: 0.2, 69 and 2569mN) and a "weighted-pin" stimulator (512mN), were assessed 45 to 75min after each BI.
RESULTS: A random effect, linear mixed model demonstrated a logarithmic correlation between elicited skin pressures (mN/mm(2)) and the SHAs (P<0.0001). No day-to-day or observer-to-observer differences in SHAs were observed. Intraclass correlation coefficients, in the range of 0.51 to 0.84, indicated a moderate to almost perfect reliability between observers. COMPARISON WITH EXISTING
METHODS: No standardized approach in SHA-assessment has hitherto been presented.
CONCLUSIONS: This is the first study to demonstrate that demarcation of secondary hyperalgesia zones depends on the developed pressure of the punctate stimulator used.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Burn injury; Mechanical hyperalgesia; Monofilaments; Punctate hyperalgesia; Secondary hyperalgesia; Sensitization

Mesh:

Year:  2015        PMID: 26310180      PMCID: PMC4651781          DOI: 10.1016/j.jneumeth.2015.08.018

Source DB:  PubMed          Journal:  J Neurosci Methods        ISSN: 0165-0270            Impact factor:   2.390


  46 in total

1.  Spatial mapping of the zone of secondary hyperalgesia reveals a gradual decline of pain with distance but sharp borders.

Authors:  J H Huang; Z Ali; T G Travison; J N Campbell; R A Meyer
Journal:  Pain       Date:  2000-05       Impact factor: 6.961

2.  Ketamine, an NMDA receptor antagonist, suppresses spatial and temporal properties of burn-induced secondary hyperalgesia in man: a double-blind, cross-over comparison with morphine and placebo.

Authors:  T Warncke; A Stubhaug; E Jørum
Journal:  Pain       Date:  1997-08       Impact factor: 6.961

3.  Effects of gabapentin in acute inflammatory pain in humans.

Authors:  M U Werner; F M Perkins; K Holte; J L Pedersen; H Kehlet
Journal:  Reg Anesth Pain Med       Date:  2001 Jul-Aug       Impact factor: 6.288

4.  Secondary hyperalgesia to punctate mechanical stimuli. Central sensitization to A-fibre nociceptor input.

Authors:  E A Ziegler; W Magerl; R A Meyer; R D Treede
Journal:  Brain       Date:  1999-12       Impact factor: 13.501

5.  The effect of changes in temperature and humidity on the accuracy of von Frey hairs.

Authors:  K Andrews
Journal:  J Neurosci Methods       Date:  1993-10       Impact factor: 2.390

6.  Von Frey's method of measuring pressure sensibility in the hand: an engineering analysis of the Weinstein-Semmes pressure aesthesiometer.

Authors:  S Levin; G Pearsall; R J Ruderman
Journal:  J Hand Surg Am       Date:  1978-05       Impact factor: 2.230

7.  Hyperbaric oxygen therapy attenuates central sensitization induced by a thermal injury in humans.

Authors:  V M Rasmussen; A E Borgen; E C Jansen; P H Rotbøll Nielsen; M U Werner
Journal:  Acta Anaesthesiol Scand       Date:  2015-03-03       Impact factor: 2.105

8.  Effect of pre- or post-traumatically applied i.v. lidocaine on primary and secondary hyperalgesia after experimental heat trauma in humans.

Authors:  H Holthusen; S Irsfeld; P Lipfert
Journal:  Pain       Date:  2000-12-01       Impact factor: 6.961

9.  Analgesic and antihyperalgesic effects of melatonin in a human inflammatory pain model: a randomized, double-blind, placebo-controlled, three-arm crossover study.

Authors:  Lars P H Andersen; Ismail Gögenur; Andreas Q Fenger; Marian C Petersen; Jacob Rosenberg; Mads U Werner
Journal:  Pain       Date:  2015-11       Impact factor: 6.961

10.  Intrathecal, but not intravenous, clonidine reduces experimental thermal or capsaicin-induced pain and hyperalgesia in normal volunteers.

Authors:  J C Eisenach; D D Hood; R Curry
Journal:  Anesth Analg       Date:  1998-09       Impact factor: 5.108

View more
  3 in total

1.  Effects of target-controlled infusion of high-dose naloxone on pain and hyperalgesia in a human thermal injury model: a study protocol: A randomized, double-blind, placebo-controlled, crossover trial with an enriched design.

Authors:  Anders D Springborg; Elisabeth K Jensen; Bradley K Taylor; Mads U Werner
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

2.  A single session of hyperbaric oxygen therapy demonstrates acute and long-lasting neuroplasticity effects in humans: a replicated, randomized controlled clinical trial.

Authors:  Anna M Wahl; Daniel Bidstrup; Isabel G Smidt-Nielsen; Mads U Werner; Ole Hyldegaard; Per Rotbøll-Nielsen
Journal:  J Pain Res       Date:  2019-07-31       Impact factor: 3.133

3.  High-dose naloxone: Effects by late administration on pain and hyperalgesia following a human heat injury model. A randomized, double-blind, placebo-controlled, crossover trial with an enriched enrollment design.

Authors:  Anders Deichmann Springborg; Elisabeth Kjær Jensen; Mads Kreilgaard; Morten Aagaard Petersen; Theodoros Papathanasiou; Trine Meldgaard Lund; Bradley Kenneth Taylor; Mads Utke Werner
Journal:  PLoS One       Date:  2020-11-12       Impact factor: 3.752

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.